Clinical Trials Logo

Filter by:
NCT ID: NCT02291029 Completed - Clinical trials for Primary Sjögren's Syndrome

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

Start date: October 22, 2014
Phase: Phase 2
Study type: Interventional

This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)

NCT ID: NCT02289690 Completed - Clinical trials for Small Cell Lung Cancer

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Start date: October 13, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).

NCT ID: NCT02289417 Completed - Ulcerative Colitis Clinical Trials

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis

UC
Start date: January 8, 2015
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).

NCT ID: NCT02288975 Completed - Sepsis Clinical Trials

Adsorbtion of Cytokines Early in Septic Shock: the ACESS Study

Start date: October 2014
Phase:
Study type: Observational

The aim of the study is to investigate the effect of CytoSorb® treatment within the first 48 hours of septic shock on organ dysfunction, microcirculation and on the cytokine storm as monitored by leukocyte activation and inflammatory mediators.

NCT ID: NCT02287922 Completed - Clinical trials for Rheumatoid Arthritis

A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

Start date: March 2015
Phase: Phase 2
Study type: Interventional

The primary objective of this study is: - To assess the efficacy and safety of dose regimens of ALX-0061 monotherapy administered subcutaneously (s.c.) to subjects with active rheumatoid arthritis (RA). The secondary objectives of this study are: - To assess the effects of ALX-0061 on quality of life, the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of ALX-0061 and to explore potential dose regimens for ALX-0061 monotherapy, based on safety and efficacy, for further clinical development. - To obtain parallel descriptive information concerning the efficacy and safety of tocilizumab (TCZ) s.c. in the same clinical trial RA population.

NCT ID: NCT02284893 Completed - Type 2 Diabetes Clinical Trials

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Start date: September 9, 2014
Phase: Phase 3
Study type: Interventional

Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.

NCT ID: NCT02283762 Completed - Clinical trials for Scleroderma, Systemic

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Start date: January 15, 2015
Phase: Phase 2
Study type: Interventional

To investigate if Riociguat is effective in the treatment of systemic sclerosis

NCT ID: NCT02282033 Completed - Bradycardia Clinical Trials

Safety and Performance Study of the Moderato System

Start date: March 2013
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the safety and performance of the Moderato System by implanting the Moderato pacemaker in patients who require a dual chamber pacemaker, and who also have hypertension, in order to reduce their blood pressure.

NCT ID: NCT02282020 Completed - Clinical trials for Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

SOLO3
Start date: February 6, 2015
Phase: Phase 3
Study type: Interventional

Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.

NCT ID: NCT02279745 Completed - Clinical trials for Pulmonary Arterial Hypertension

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

Start date: July 8, 2015
Phase: Phase 2
Study type: Interventional

This study was an open-label extension study to determine the long-term safety and tolerability of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) who have completed Study APD811-003, or who were assigned to receive placebo and were discontinued due to clinical worsening.